Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jacobio Pharmaceuticals has announced that China’s CDE has approved their Investigational New Drug application for JAB-23E73, a Pan-KRAS inhibitor aimed at treating various tumor mutations. The drug, which has already had its IND application approved by the U.S. FDA, is poised to enter phase I/IIa clinical trials for advanced solid tumor patients in China and the U.S. This development could potentially benefit the yearly 2.7 million new patients with KRAS-related mutations.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.